<DOC>
	<DOC>NCT02220868</DOC>
	<brief_summary>The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.</brief_summary>
	<brief_title>Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study</brief_title>
	<detailed_description>The objective of this study is to evaluate the safety, efficacy and pharmacokinetics of sofosbuvir 400mg once daily plus ribavirin 1000-1200 mg daily in HIV-infected patients on fixed dose co-formulation emtricitabine/tenofovir/cobicistat/elvitegravir (Stribild).</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>18 years of age or older Chronic HCV genotype 1 infection Receiving emtricitabine/tenofovir/cobicistat/elvitegravir for at least 8 weeks. CD4 count &gt;200 cells/mm3 at screening and no CD4 count &lt;200 in previous 12 weeks HIV RNA PCR &lt;50 copies/ml at screening and no HIV RNA PCR &gt; 200 copies/ml in previous 12 weeks History of integrase inhibitor resistance History of integrase inhibitor failure Absolute neutrophil counts under 1500/mm3 ( Black/ African Americans &lt;1200/mm3 Patients with cirrhosis Platelet count under 90,000 per cubic millimeter Hemoglobin levels &lt;11 gm/dl in women or &lt;12 gm/dl in men Previous treatment with a DAA Hepatocellular carcinoma AFP&gt;100 ng/mL hepatitis B virus (HBsAg positive) Evidence of decompensated liver disease including, but not limited to, a history of presence of clinical ascites, bleeding varices, or hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>DAA</keyword>
</DOC>